Graves’ Disease

Anti-TSHR Antibody (M22) is a selective agonist targeting TSHR (thyroid-stimulating hormone receptor), acting through competitive binding to the extracellular domain of TSHR. Anti-TSHR Antibody (M22) can mimic the biological effects of thyroid-stimulating hormone (TSH), activating downstream cAMP-PKA and other signaling pathways. Anti-TSHR Antibody (M22) can stimulate the proliferation of thyroid follicular epithelial cells and human umbilical vein endothelial cells (HUVECs), promote angiogenesis and tube formation, cell migration, and also upregulate the expression of angiogenesis-related proteins such as PROX1. Anti-TSHR Antibody (M22) can be used in research areas such as the mechanisms of goiter formation in Graves' disease (GD), angiogenesis regulation, and TSHR antagonist screening.

Methimazole (Thiamazole) is an anti-thyroid agent, which blocks thyroid hormone production from the thyroid gland. Metamizol can cause hepatotoxicity.

Org 274179-0 is a low-molecular-weight allosteric thyrotropin receptor (TSH Receptor) antagonist with equipotent follicle-stimulating hormone receptor antagonistic activity and selectivity for the luteinizing hormone receptor. Org 274179-0 binds to the transmembrane domain of the thyrotropin receptor, stabilizes the receptor's inactive state, and blocks agonist-induced and constitutive signaling through the adenylyl cyclase/cAMP and phospholipase C pathways. Org 274179-0 can be used for research on Graves' disease and Graves' ophthalmopathy.

Progoitrin is an orally active glucosinolate. As the precursor of goitrin (HY-N0224A), an antithyroid compound, progoitrin releases goitrin via hydrolysis by myrosinase or gastrointestinal glucosidase. Progoitrin converts to goitrin in vivo and exerts antithyroid activity by inhibiting the accumulation of radioactive iodine in the thyroid gland. Progoitrin can be used in the research of Graves' disease (thyrotoxicosis).

Progoitrin potassium is an orally active glucosinolate. As the precursor of goitrin (HY-N0224A), an antithyroid compound, progoitrin releases goitrin via hydrolysis by myrosinase or gastrointestinal glucosidase. Progoitrin converts to goitrin in vivo and exerts antithyroid activity by inhibiting the accumulation of radioactive iodine in the thyroid gland. Progoitrin potassium can be used in the research of Graves' disease (thyrotoxicosis).

Dioscoreae nipponicae rhizoma extract (Szechuan lovage rhizome extract) is a rhizome extract of Dioscorea nipponica that can promote cell apoptosis.